Aruna Bio Announces Issuance of U.S. Patent for Method of Use for Neural Exosomes Used to Reduce Inflammation in the Brain
August 19, 2024 08:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the...
Aruna Bio Announces Issuance of U.S. Patent for Composition of Matter for Neural Exosomes Used to Deliver Therapeutics to the Brain
July 16, 2024 08:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., July 16, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that the...
Aruna BIO Announces Appointment of Lynn Swann to its Board of Directors
June 03, 2024 07:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., June 03, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced the...
Aruna Bio to Present at BIO International Convention 2024
May 28, 2024 07:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., May 28, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative conditions, today announced that...
Aruna Bio to Participate in Upcoming Investor Conferences
March 18, 2024 08:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced that...
Aruna BIO Establishes Stroke Advisory Board to Advance Lead Program, AB126 into the Clinic
March 04, 2024 08:00 ET
|
Aruna Bio
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome platform and lead program– -Phase 1b/2a clinical trial in...
Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication
January 16, 2024 08:00 ET
|
Aruna Bio
-Phase 1b/2a clinical trial in acute ischemic stroke expected to initiate in 1H 2024- -Marks the first IND for Aruna’s platform with plans to expand AB126, an unmodified exosome derived from...
Aruna Bio to Participate in the BIO Investor Forum in October 2023
October 10, 2023 08:00 ET
|
Aruna Bio
BOSTON and ATHENS, Ga., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today...
Aruna Bio Announces Presentation on the Mechanism of its Neural Exosome Platform and Lead Program, AB126, at the BioProcess International Conference & Exhibition
September 18, 2023 08:02 ET
|
Aruna Bio
– AB126, an unmodified exosome derived from neural stem cells, shows native therapeutic activity with anti-inflammatory and neuroprotective properties through modulation of the ATP-adenosine axis – ...
Aruna Bio Announces Preclinical Results from Pilot Study Evaluating AB126 for the Treatment of Amyotrophic Lateral Sclerosis
September 07, 2023 16:05 ET
|
Aruna Bio
- Data from superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) mouse model demonstrated prolonged survival and reduced inflammation in the spinal cord – -AB126, an unmodified exosome...